CD28, in contrast to CD200, did not show significant differences between myeloma cohorts, but was increased in ID (Figure 2A), thus allowing the distinction between aPC and nPC (Figure 2A and Supplementary Figure S2). This evidence concerns the gene CD28 and plasma cell myeloma.